Recent preclinical data suggested that the engagement of FcγRs could augment the anti-tumor activity of anti-PD-L1 antibodies via the ADCC effect against the PD-L1+ immune suppressive myeloid cells (88) or tumor cells (89). Here, CD274 is linked to neoplasm.